Despite evolutions in cardiac therapy, interventional and surgical techniques, the occurrence of congestive heart failure (CHF) remains a major cause of morbidity and mortality in patients suffering from acute myocardial infarct representing actually the most common cause of death.

The worldwide CHF annual incidence is estimated over 1 million new patients in the U.S, Europe and Japan for a global cost over € 50 billions for the number one health threat.